NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
9.11
-0.51 (-5.30%)
Mar 31, 2025, 9:39 AM EDT - Market open
NeoGenomics Revenue
In the year 2024, NeoGenomics had annual revenue of $660.57M with 11.65% growth. NeoGenomics had revenue of $172.00M in the quarter ending December 31, 2024, with 10.57% growth.
Revenue (ttm)
$660.57M
Revenue Growth
+11.65%
P/S Ratio
1.84
Revenue / Employee
$300,257
Employees
2,200
Market Cap
1.17B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 660.57M | 68.92M | 11.65% |
Dec 31, 2023 | 591.64M | 81.92M | 16.07% |
Dec 31, 2022 | 509.73M | 25.40M | 5.24% |
Dec 31, 2021 | 484.33M | 39.88M | 8.97% |
Dec 31, 2020 | 444.45M | 35.62M | 8.71% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NEO News
- 21 days ago - NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline - Business Wire
- 4 weeks ago - NeoGenomics: Decent Fundamentals, But Still Overvalued - Seeking Alpha
- 5 weeks ago - NeoGenomics to Participate in Upcoming Investor Conferences - Business Wire
- 5 weeks ago - NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - NeoGenomics Reports Fourth Quarter and Full Year 2024 Results - Business Wire
- 2 months ago - NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025 - Business Wire
- 2 months ago - NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan - Business Wire
- 2 months ago - NeoGenomics Announces Chief Executive Officer Succession - Business Wire